FDA approves landmark pancreatic cancer drug that's shown to improve survival
Reported byNPR Health ↗·Sourced by Goodlede
The FDA approved daraxonrasib, a first-of-its-kind drug blocking a mutated protein in more than 90% of pancreatic cancer cases. In trials, patients taking the drug nearly doubled their survival time to 13.2 months compared with 6.7 months for chemotherapy, with fewer severe side effects.
This is not a cure. The drug offers meaningful improvement for advanced, metastatic pancreatic cancer that has stopped responding to prior treatment; outcomes for early-stage disease or other patient populations may differ.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at NPR Health
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede